Disclosed is a CD154 binding polypeptide that specifically recognizes CD154. The polypeptide according to the present disclosure effectively inhibits the CD154-CD40 interaction without activating platelets, and thus can be effectively used in the prevention or treatment of various T cell-mediated or antibody-mediated diseases or symptoms, which requires inhibition of the interaction.